INT92574

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 2000
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 51
Total Number 51
Disease Relevance 24.87
Pain Relevance 11.89

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (CXCL5) extracellular space (CXCL5) extracellular region (CXCL5)
cell-cell signaling (CXCL5)
Anatomy Link Frequency
neutrophil 10
plasma 3
endothelial cells 3
leukocyte 2
smooth muscle cells 1
CXCL5 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 1229 100.00 Very High Very High Very High
cytokine 164 100.00 Very High Very High Very High
chemokine 894 99.88 Very High Very High Very High
rheumatoid arthritis 377 98.96 Very High Very High Very High
depression 35 98.00 Very High Very High Very High
Prostatitis 3 97.44 Very High Very High Very High
pain pelvic 2 96.64 Very High Very High Very High
dexamethasone 2 96.60 Very High Very High Very High
corticosteroid 57 96.04 Very High Very High Very High
Kinase C 3 89.76 High High
Disease Link Frequency Relevance Heat
INFLAMMATION 1207 100.00 Very High Very High Very High
Colon Cancer 63 99.84 Very High Very High Very High
Schizophrenia 50 99.76 Very High Very High Very High
Acute Coronary Syndrome 1330 99.12 Very High Very High Very High
Rheumatoid Arthritis 377 98.96 Very High Very High Very High
Lung Cancer 2 98.34 Very High Very High Very High
Depression 38 98.00 Very High Very High Very High
Hypoxia 91 97.88 Very High Very High Very High
Cardiovascular Disease 337 97.62 Very High Very High Very High
Benign Prostatic Hypertrophy 5 97.44 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
There are several possible reasons for the disparate impact of atorvastatin on CXCL5 expression in non-stimulated and stimulated conditions.
Gene_expression (expression) of CXCL5
1) Confidence 0.78 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 0.27 Pain Relevance 0.14
in HUVECs, the preponderant drug effect manifested as a reduction of ENA-78 protein concentrations (presumable through a post-transcriptional mechanism) with no impact on CXCL5 expression.
Gene_expression (expression) of CXCL5
2) Confidence 0.78 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 0.05 Pain Relevance 0.03
In experiments investigating the impact of atorvastatin dose on ENA-78 production, HUVECs were pre-treated with atorvastatin followed by addition of IL-1?
Gene_expression (production) of ENA-78
3) Confidence 0.78 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 0 Pain Relevance 0
Relative CXCL5 gene expression was determined by the 2???
Gene_expression (expression) of CXCL5
4) Confidence 0.78 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 0.35 Pain Relevance 0.06
CXCL5 (MIM 600324) was chosen as our a priori candidate gene based on 1) the known role of the neutrophil pathway in cardiovascular diseases including ACS [39]–[41], and 2) our previously published data demonstrating atorvastatin to significantly lower basal production of endothelial ENA-78 [15].
Gene_expression (production) of ENA-78 in neutrophil associated with acute coronary syndrome and cardiovascular disease
5) Confidence 0.78 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 0.76 Pain Relevance 0.30
and atorvastatin in the presence or absence of mevalonate, FPP, and GGPP to determine whether atorvastatin inhibition of ENA-78 production was dependent on HMG-CoA reductase inhibition and subsequent downstream pathways.
Gene_expression (production) of ENA-78
6) Confidence 0.78 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 0 Pain Relevance 0
We also investigated whether statin use, a potent modulator of inflammation, modifies CXCL5's association with outcomes and characterized the in vitro effect of atorvastatin on endothelial ENA-78 production.
Gene_expression (production) of ENA-78 associated with inflammation
7) Confidence 0.78 Published 2008 Journal PLoS ONE Section Abstract Doc Link PMC2518836 Disease Relevance 0.75 Pain Relevance 0.21
Furthermore, CXCL5 expression has been shown to be highly inducible in endothelial and vascular smooth muscle cells by IL-1?
Gene_expression (expression) of CXCL5 in smooth muscle cells
8) Confidence 0.78 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 1.30 Pain Relevance 0.44
156C carriers exhibit significantly greater plasma concentrations of ENA-78 and greater ENA-78 production from cultured leukocytes [13].
Gene_expression (production) of ENA-78 in plasma
9) Confidence 0.78 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 0.41 Pain Relevance 0.28
ENA-78 protein concentrations and CXCL5 gene expression levels were compared for all conditions by one-way ANOVA with Tukey correction for multiple comparisons.
Gene_expression (expression) of CXCL5
10) Confidence 0.78 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 0.41 Pain Relevance 0.07
stimulated production of ENA-78 at 4, 12, 24, and 48 hours by 0%, 30%, 59% (p?
Gene_expression (production) of ENA-78
11) Confidence 0.68 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 0.07 Pain Relevance 0.04
Nonetheless, we have previously shown that CXCL5 genotype is a predictor of circulating ENA-78 concentrations and leukocyte production of ENA-78 [13].
Gene_expression (production) of ENA-78 in leukocyte
12) Confidence 0.68 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 0.18 Pain Relevance 0
Nonetheless, we have previously shown basal endothelial ENA-78 protein production to be reduced by atorvastatin in a dose-dependent fashion, and currently extend this observation to a pro-inflammatory state [15].
Gene_expression (production) of ENA-78 protein associated with inflammation
13) Confidence 0.68 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 0.31 Pain Relevance 0.16
-mediated ENA-78 production in a dose- and time-specific manner, through pathways involving HMG-CoA reductase and prenylation proteins.
Gene_expression (production) of ENA-78
14) Confidence 0.68 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 0.42 Pain Relevance 0.10
156G>C (rs352046) single nucleotide polymorphism (SNP) in the CXCL5 promoter region to occur with high minor allele frequency in the general population and associate with both elevated plasma ENA-78 concentrations and leukocyte production of ENA-78 [13].
Gene_expression (production) of ENA-78 in plasma
15) Confidence 0.68 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 1.05 Pain Relevance 0.26
We tested the hypothesis that variation in the chemokine gene CXCL5, which encodes epithelial neutrophil-activating peptide (ENA-78), is associated with ACS prognosis.
Gene_expression (encodes) of CXCL5 in neutrophil associated with chemokine and acute coronary syndrome
16) Confidence 0.68 Published 2008 Journal PLoS ONE Section Abstract Doc Link PMC2518836 Disease Relevance 0.62 Pain Relevance 0.19
PCR for both CXCL5 and GAPDH were performed in parallel reactions using the following conditions: 95°C for 2 minutes; 35 cycles of 95°C for 30 seconds, 59°C for 30 seconds, and 72°C for 30 seconds; followed by 7 minutes of elongation at 72°C.


Gene_expression (PCR) of CXCL5
17) Confidence 0.68 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 0.14 Pain Relevance 0
We tested the hypothesis that variation in the chemokine gene CXCL5, which encodes epithelial neutrophil-activating peptide (ENA-78), is associated with ACS prognosis.
Gene_expression (encodes) of ENA-78 in neutrophil associated with chemokine and acute coronary syndrome
18) Confidence 0.68 Published 2008 Journal PLoS ONE Section Abstract Doc Link PMC2518836 Disease Relevance 0.68 Pain Relevance 0.22
We have previously demonstrated CXCL5 ?
Gene_expression (demonstrated) of CXCL5
19) Confidence 0.68 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 0.42 Pain Relevance 0.30
156C carriers exhibit significantly greater plasma concentrations of ENA-78 and greater ENA-78 production from cultured leukocytes [13].
Gene_expression (production) of ENA-78 in plasma
20) Confidence 0.68 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2518836 Disease Relevance 0.41 Pain Relevance 0.29

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox